ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Canonical disease-defining genomic rearrangements, such as the BCR–ABL1 fusion in chronic myeloid leukemia, are routinely monitored in hematological malignancies to assess treatment response [116, 117].